An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Pfizer
Study ID
NCT07426757
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Cancer
  • Advanced Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PF-07994525 — DRUG
    Oral administration
  • Midazolam — DRUG
    Oral administration

Study Details

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

Key Dates

Start date
May 15, 2026
Status verified
May 2026
Primary completion
Jul 10, 2029
Completion
Jul 10, 2030

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1
    Monotherapy Dose Escalation
  • Experimental: Part 2
    Monotherapy Dose Expansion

Primary Outcome Measure

Type, incidence and severity of participants with adverse events (AEs) [ Time Frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research Institute - PharmacyNashvilleTennessee37203-
SCRI Oncology PartnersNashvilleTennessee37203-
Tristar BMTNashvilleTennessee37203-
TriStar Centennial Medical centerNashvilleTennessee37203-

Find similar trials in Nashville, TN

By research site
Sarah Cannon Research Institute - Pharmacy· Nashville, TNSCRI Oncology Partners· Nashville, TNTristar BMT· Nashville, TNTriStar Centennial Medical center· Nashville, TN

Related Studies